RecruitingPhase 3NCT05943535
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- United Therapeutics
- Intervention
- Placebo(drug)
- Enrollment
- 698 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- UAB Lung Health Center, Birmingham, Alabama, United States
- Banner University Medical Center Phoenix Lung Institute, Phoenix, Arizona, United States
- Norton Thoracic Institute, Phoenix, Arizona, United States
- Peter Morton Medical Building, Los Angeles, California, United States
- NewportNativeMD, Inc., Newport Beach, California, United States
- University of California Irvine Medical Center, Orange, California, United States
- Paradigm Clinical Research, Redding, California, United States
- UC Davis Health Medical Center, Sacramento, California, United States
- Paradigm Clinical Research, San Diego, California, United States
- Stanford University Medical Center, Stanford, California, United States
- Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Ascension Medical Group St. Vincent's Lung Institute, Jacksonville, Florida, United States
- Mayo Clinic, Jacksonville, Florida, United States
- TGH/USF Center for Advanced Lung Disease and Lung Transplant, Tampa, Florida, United States
- The Emory Clinic, Atlanta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05943535 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics